SABS · SAB Biotherapeutics, Inc.
$2.92
-0.06 (-2.01%)
At close · Oct 12
Return incl. dividend (before tax)
Market Cap
$271.14M
Shares
90.99M
Volume · Oct 12
39.31K
Avg daily vol (3M)
500.25K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.98
Open$2.91
Day$2.81–3.02
52W close$2.17–4.59
Avg vol 30d584K
Short int4.3M · 4.7% float · 5.0d
Short vol58%
Last earningsAug 6, 2026
DataFeb 2021–Oct 2026
Filing10-Q · Aug 6
Up next
filed Aug 6, 2026
call held Aug 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$2.78M
Trailing 12 months
Net income (TTM)
−$12.78M
Trailing 12 months
Revenue growth YoY
+207.7%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
13.0
Trailing earnings · reciprocal yield 7.7%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$102.63M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+758.1%
Year over year · more shares
Price change (1Y)
+19.2%
Trailing year
Short interest
4.7%
Latest settlement · 5.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 14.8 · calm
Equity put/call 0.56
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−21%
below
Price vs 50-day avg
−16%
below
RSI (14)
35
neutral
MACD trend
Negative
52-week position
33%
mid-range
Momentum
relative strength
1-month return
−13%
trailing
6-month return
−23%
trailing
YTD return
−20%
this year
Relative strength
−33%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow
Accumulating
1 of 93 funds reported for Sep 30 · net +21 sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
4.72% of float · ▲ +19.1% MoM · 5.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
93 holders — near 3-yr high, broad support
Squeeze score
70
elevated · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
+79%
Y/Y
Free cash flow
$-45.7M
Quant / Vol
risk profile
Volatility
64%
annualized · 1-yr
Max drawdown
−37%
past year
ATR
6.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Mar 31, 2023
Annualized anticipated net cash consumption
· annualized
$18M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−21%
Bearish
Price vs 50-day avg
−16%
Bearish
RSI (14)
35
Neutral
MACD trend
Negative
Bearish
52-week position
33%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow
Accumulating
1 of 93 funds reported for Sep 30 · net +21 sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
4.72% of float · ▲ +19.1% MoM · 5.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
93 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2
Now $3 · 33%
Range high $5
vs 200-day avg -21%
vs 50-day avg -16%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SABS
this stock
SAB Biotherapeutics, Inc.
|
$271.14M | -20.3% | -100.0% | — | 4.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$129.29B | +12.5% | +46.2% | 29.7 | 1.8% |
|
MRNA
Moderna, Inc.
|
$89.83B | +663.0% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$76.86B | -3.3% | +20.8% | 18.5 | 2.1% |
|
CSLLY
Csl Ltd
|
$61.83B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SABS | +0.0% | -12.6% | -22.8% | -6.0% | -20.3% |
| SPY | +1.2% | +1.9% | +9.9% | +2.1% | +14.2% |
| vs SPY | -1.2% | -14.5% | -32.7% | -8.1% | -34.5% |